IBRX270319C00012000
IBRX Mar 19 2027 12.00 Call
optionOPRA
EODOct 16, 2026
1.40USD-31.707%(-0.65)3Vol385OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
12
Expiration
Mar 19, 2027
DTE
150d
Moneyness
OTM
Intrinsic
$0.00
IBRX 12 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | -50.00% | 125 | 190 |
| Oct 30, 2026 | 10d | $0.10 | -67.74% | 12 | 62 |
| Nov 6, 2026 | 17d | $0.40 | -18.37% | 17 | 307 |
| Nov 13, 2026 | 24d | $0.51 | -32.00% | 168 | 213 |
| Nov 20, 2026 | 31d | $0.36 | -40.00% | 197 | 7,815 |
| Nov 27, 2026 | 38d | $0.85 | -6.59% | 2 | 3 |
| Dec 18, 2026 | 59d | $1.00 | +0.00% | 210 | 208 |
| Jan 15, 2027 | 87d | $1.00 | -31.03% | 717 | 10,602 |
| Mar 19, 2027 | 150d | $1.40 | -31.71% | 3 | 385 |
| Apr 16, 2027 | 178d | $1.80 | -25.00% | 180 | 176 |
| May 21, 2027 | 213d | $3.00 | +15.38% | 1 | 240 |
| Aug 20, 2027 | 304d | $2.23 | -23.89% | 5 | 50 |
| Nov 19, 2027 | 395d | $3.56 | +18.67% | 2 | 19 |
| Jan 21, 2028 | 458d | $2.70 | -20.59% | 16 | 1,740 |
| Mar 17, 2028 | 514d | $4.01 | +14.57% | 4 | 210 |
| Jan 19, 2029 | 822d | $5.00 | +3.52% | 1 | 18 |
IBRX Nearby Strikes · Mar 19, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 6 C | $4.45 | -3.26% | 2 | 17 | ITM |
| 7 C | $4.03 | -4.05% | 1 | 255 | ITM |
| 8 C | $3.00 | -11.76% | 59 | 1,300 | ITM |
| 9 C | $2.30 | -24.09% | 73 | 428 | OTM |
| 10 C | $2.20 | -21.43% | 192 | 1,298 | OTM |
| 11 C | $1.60 | -41.82% | 11 | 921 | OTM |
| 12 C | $1.40 | -31.71% | 3 | 385 | OTM |
| 13 C | $2.00 | +42.86% | 5 | 23 | OTM |
| 14 C | $1.50 | -25.74% | 5 | 30 | OTM |
| 15 C | $0.95 | -40.63% | 2 | 2,008 | OTM |
| 16 C | $1.66 | -12.63% | 6 | 55 | OTM |
| 17 C | $0.70 | -29.29% | 25 | 51 | OTM |
| 18 C | $1.20 | +20.00% | 50 | 59 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.